MissionIR Articles
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Achieves Critical Milestone for Production of Lead Drug Candidate
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its GMP manufacturer partner NCK A/S,…
-
CNS Pharmaceuticals, Inc. (CNSP) Expands Scientific Advisory Board with Leading Neuro-Oncology Expert, Dr. Patrick Wen, M.D.
Pivotal Phase 2 Berubicin trial expected to commence in Q1 2021 following planned IND submission in Q4 2020 CNS Pharmaceuticals also plans to begin pre-clinical work on Berubicin in connection with treatment for lymphomas, pancreatic,…
-
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is “One to Watch”
CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Partners with Leading Medical Imaging Group for Upcoming Berubicin Clinical Trials
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has announced that it will partner with Image Analysis Group (“IAG”)…
-
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Mines Investment-building Opportunity for Brain Tumor-Targeting Drug Candidate at Annual Conference
CNS Pharmaceuticals is a clinical-stage biotechnology company developing therapies to combat aggressive cancers of the brain and central nervous system The company will be applying for approval to launch Phase II trials in the first…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP), Sub-Licensee Partner Advancing Lead Drug Candidate in First-Ever Phase 1 and Phase 2 Clinical Trials
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing its leading drug candidate, Berubicin, to move…
Search Articles
Latest Articles
- MissionIRNewsBreaks – MindWave Innovations Inc. (NYSE American: APUS) Offers Secure Gateway to Digital Assets
- VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline
- MissionIRNewsBreaks – Greenland Energy Company (NASDAQ: GLND) Advances Jameson Land Basin Toward Exploration Drilling
- MissionIRNewsBreaks – Massimo Group (NASDAQ: MAMO) Terminates Proposed FST Acquisition, Refocuses on Internal Security Technology Development
- MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis